KR20220130966A - Composition for Prophylaxis or Treatment of Osteoporosis or Menopause-Related Decreased Motility Comprising Fermented Antler Extract - Google Patents
Composition for Prophylaxis or Treatment of Osteoporosis or Menopause-Related Decreased Motility Comprising Fermented Antler Extract Download PDFInfo
- Publication number
- KR20220130966A KR20220130966A KR1020210035876A KR20210035876A KR20220130966A KR 20220130966 A KR20220130966 A KR 20220130966A KR 1020210035876 A KR1020210035876 A KR 1020210035876A KR 20210035876 A KR20210035876 A KR 20210035876A KR 20220130966 A KR20220130966 A KR 20220130966A
- Authority
- KR
- South Korea
- Prior art keywords
- antler
- fermented
- extract
- antler extract
- osteoporosis
- Prior art date
Links
- 210000003056 antler Anatomy 0.000 title claims abstract description 91
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 230000004899 motility Effects 0.000 title claims abstract description 14
- 230000003247 decreasing effect Effects 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims description 9
- 238000011321 prophylaxis Methods 0.000 title description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 25
- 239000004310 lactic acid Substances 0.000 claims abstract description 25
- 241000894006 Bacteria Species 0.000 claims abstract description 23
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 241000282994 Cervidae Species 0.000 claims description 16
- 108091005804 Peptidases Proteins 0.000 claims description 14
- 102000035195 Peptidases Human genes 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 241000194036 Lactococcus Species 0.000 claims description 2
- 241000192132 Leuconostoc Species 0.000 claims description 2
- 241000192001 Pediococcus Species 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 230000009245 menopause Effects 0.000 description 15
- 238000000605 extraction Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000011164 ossification Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000009806 oophorectomy Methods 0.000 description 4
- 239000003075 phytoestrogen Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012263 liquid product Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 2
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- -1 flax seed lignan Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 부작용 없이 안전하게 복용할 수 있는 골다공증이나 여성 갱년기 관련 운동성 감소의 예방 또는 치료/증상개선에 효과적인 조성물에 관한 것이다. The present invention relates to a composition effective for preventing or treating/improving symptoms of osteoporosis or female menopause-related reduced mobility, which can be safely taken without side effects.
여성의 갱년기는 여성의 생식기능이 소실되는 월경 폐지로부터 1~2년의 기간으로, 성성숙기에서 노년기로 이행하는 시기이다. 갱년기의 연령은, 체질·영양상태·분만횟수 등에 따라 개인차가 있고 평균 수명의 연장으로 폐경기가 약간 늦어지는 경향이 있으나, 통계적으로는 45~55세로 본다. A woman's menopause is a period of 1 to 2 years from the abolition of menstruation, when the female reproductive function is lost, and it is a period of transition from sexual maturity to old age. The age of menopause varies from person to person depending on constitution, nutritional status, and frequency of childbirth, and menopause tends to be slightly delayed due to the extension of life expectancy, but statistically it is considered to be 45 to 55 years old.
폐경 이전부터 인체 내에서는 에스트로겐과 프로게스테론의 분비가 점차 감소하며, 이에 따른 호르몬의 부족 현상으로 갱년기 증상이 나타나게 된다. 가장 흔한 여성 갱년기 증상의 하나는 골다공증으로, 조직 대사의 이상으로 인하여 뼈의 용식은 계속되는 반면 뼈의 형성이 거의 중단되기 때문에 발생한다. 골다공증은 폐경기 후 여성에게 가장 흔히 발생하지만 영양 부족이나 활동 감소에 의해서도 생길 수 있다. 갱년기의 다른 증상으로 안면 홍조, 빈맥, 발한, 피로감, 불안감, 우울, 기억력 감퇴, 불면증, 근력 약화 등이 수반되기도 한다.Before menopause, the secretion of estrogen and progesterone in the human body gradually decreases, and the symptoms of menopause appear due to the lack of hormones. One of the most common symptoms of menopause in women is osteoporosis, which occurs because bone formation is almost stopped while bone erosion continues due to abnormal tissue metabolism. Osteoporosis is most common in postmenopausal women, but can also be caused by malnutrition or reduced activity. Other symptoms of menopause include hot flashes, tachycardia, sweating, fatigue, anxiety, depression, memory loss, insomnia, and muscle weakness.
호르몬 보충 요법은 갱년기 증상 완화에 가장 효과적인 방법이다. 여성 호르몬을 투여하면 골밀도가 증가하여 골절이 감소한다고 알려졌으며, 폐경 후 피부의 탄력과 두께를 유지하는 데에도 효과가 있다. 그러나 자궁내막암이나 유방암 같은 호르몬 의존성 종양 병력이 있는 경우에는 호르몬 보충 요법에 의해 재발의 위험성이 증가하며, 고혈압, 혈전증, 담도계 결석, 비정상 자궁 출혈 등을 유발할 위험이 있다. Hormone replacement therapy is the most effective way to relieve menopausal symptoms. It is known that the administration of female hormones increases bone density and reduces fractures, and it is also effective in maintaining the elasticity and thickness of the skin after menopause. However, if there is a history of hormone-dependent tumors such as endometrial cancer or breast cancer, hormone replacement therapy increases the risk of recurrence, and there is a risk of causing hypertension, thrombosis, biliary stones, and abnormal uterine bleeding.
이러한 문제점 때문에 에스트로겐과 같은 활성을 나타내면서도 부작용이 없는 식물 유래의 천연 에스트로겐을 이용한 연구가 활발히 진행되고 있다. 일반적으로 파이토에스트로겐(phytoestrogen)이라고 불리는 식물성 에스트로겐은 에스트로겐과 매우 유사한 구조 및 기능을 가지는 물질로 대두의 이소플라본(isoflavone)과 아마종자의 리그난(lignan) 등이 알려져 있다. 그러나 갱년기 증상 완화에 있어서 이러한 식물성 에스트로겐의 직접적인 효과가 아직까지 명확하게 밝혀지지 않았으며, 식물성 에스트로겐 역시 장기간 복용 시 뇌졸중, 심장병, 유방암 발생에 대한 가능성이 보고된 바 있다.Because of these problems, studies using natural plant-derived estrogen without side effects while exhibiting the same activity as estrogen are being actively conducted. In general, phytoestrogens, called phytoestrogen, are substances having a structure and function very similar to estrogen. Soybean isoflavone and flax seed lignan are known. However, the direct effect of these phytoestrogens in relieving menopausal symptoms has not yet been clearly elucidated, and phytoestrogens have also been reported to have potential for stroke, heart disease, and breast cancer if taken for a long time.
사슴의 뿔은 해마다 번식기를 중심으로 탈락되고 다시 생긴다. 녹용은 봄, 여름에 구각이 탈락되고 새로 나는 뿔로, 아직 각질이 형성되지 않아 내부에 혈관이 있고 유연한 성질을 띠는 것을 채취하여 건조시킨 것이다. 뿔이 자람에 따라 피가 마르고, 내부의 칼슘이 단단하게 골질화된 것을 녹각이라 하며, 피 성분이 모두 사라지고 석회질이 되어 자연 탈락된 것을 낙각이라 한다. The deer's antlers fall off and reappear every year around the breeding season. Antler antlers are antlers that have been removed from the mouth in spring and summer, and are dried after collecting and drying those that have blood vessels inside and are flexible because keratin has not yet been formed. As the horn grows, the blood dries up and the calcium inside is hardened to ossification is called antler.
녹용의 성질은 따뜻하고 독이 없으며, 맛은 달고 짜다. 주로 간과 신장, 심장, 심포에 작용하여, 생식·성장 등의 기본적인 생리기능을 보충하는 것으로 알려져 있다. 한방에서는 녹용을 예로부터 최고의 보혈 강장제로 여겨왔으며, 동의보감 등의 문헌에 수록된 바와 같이 녹용에는 강장작용, 보기혈 작용, 강정 작용, 진통 작용, 조혈 작용, 생장 발육 촉진 작용, 심부전증 치료 작용 및 기능 항진 작용 등이 있으며, 이 밖에도 피로회복, 신체 활력 증강, 골 흡수 억제효능 및 신기능 강화 등 다양한 효능이 입증되었다. 그러나 녹용은 설사 등의 부작용이 있어, 한방에서 수렴작용이 있는 한방재료와 복방 처방으로 다양한 질병의 예방과 치료에 사용되고 있으나, 이 경우에는 기대했던 효과가 상실되거나 감소될 우려가 있다. 이에 녹용 추출물의 흡수를 용이하게 하면서도 기능성을 증가시킬 수 있는 처리방법이 요구된다.The nature of antler is warm and non-toxic, and the taste is sweet and salty. It is known to mainly act on the liver, kidney, heart, and pericardium to supplement basic physiological functions such as reproduction and growth. In oriental medicine, deer antler has been regarded as the best blood tonic since ancient times, and as recorded in Donguibogam et al. In addition, various effects such as recovery from fatigue, enhancement of physical vitality, inhibition of bone resorption and strengthening of renal function have been proven. However, deer antlers have side effects such as diarrhea, and are used for the prevention and treatment of various diseases as herbal ingredients with an astringent action in oriental medicine and as a prescription for abdominal medicine, but in this case, the expected effect may be lost or reduced. Accordingly, there is a need for a treatment method capable of increasing functionality while facilitating absorption of the deer antler extract.
현대사회는 지속적인 경제성장과 더불어 생활수준이 향상되고 있으나 복잡해지는 사회 생활에 따른 스트레스와 식생활 불균형으로 인하여 다양한 질병이 증가하고 있으며, 건강기능식품을 통하여 이를 예방하고 관리하기 위한 수요가 증가하고 있는 추세이다. 최근의 건강기능식품은 단순히 기능성만이 강조된 것을 넘어서 복용이 편리하고 관능성을 향상시킨 제품들이 개발되어 유통되고 있다. 녹용은 동물성 소재로 단백질과 회분의 함량이 높고, 동물성 특이의 맛으로 인하여 제품 개발에 제한이 있었다. 또한 녹용에 다량으로 함유된 고분자 단백질은 열수 또는 알코올 추출 시 함께 추출되어 농축되면서 침전물을 형성함으로써 녹용의 액상 제품류 개발에 주된 장애 요인으로 대두되어 왔다.In modern society, the standard of living is improving along with the continuous economic growth, but various diseases are increasing due to stress and dietary imbalances caused by complex social life, and the demand for preventing and managing them through health functional foods is increasing. to be. In recent years, health functional foods have been developed and distributed products that are convenient to take and have improved sensuality beyond simply emphasizing functionality. Deer antler is an animal material, high in protein and ash, and has limited product development due to the peculiar taste of animal origin. In addition, the high molecular weight protein contained in antlers is extracted with hot water or alcohol during extraction and concentrated to form a precipitate, which has emerged as a major obstacle to the development of liquid products of antler.
본 발명은 상기와 같은 종래기술의 문제를 해결하기 위하여, 호르몬 의존성 종양의 우려가 있는 호르몬 제제 또는 호르몬 유사제가 아니면서 골다공증과 여성 갱년기 관련 운동성 감소의 예방 또는 치료/증상개선에 효과적인 조성물을 제공하는 것을 목적으로 한다.In order to solve the problems of the prior art as described above, the present invention provides a composition effective for preventing or treating/improving symptoms of osteoporosis and women's menopausal-related reduced mobility without being a hormone agent or a hormone mimic that has a risk of hormone-dependent tumors. aim to
본 발명의 다른 목적은 장내 흡수를 돕고 동물성 특유의 냄새와 맛을 제거하며, 액상 제품에서도 침전 형성을 억제하여 관능성이 우수한 녹용 발효추출물을 함유하는 조성물을 제공하는 것을 목적으로 한다.Another object of the present invention is to provide a composition containing a fermented antler ferment extract having excellent organoleptic properties by helping intestinal absorption, removing odor and taste peculiar to animals, and suppressing the formation of precipitates even in liquid products.
전술한 목적을 달성하기 위한 본 발명은 유산균에 의해 발효된 녹용 발효추출물을 포함하는 골다공증 또는 여성 갱년기 운동성 감소의 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention for achieving the above object relates to a pharmaceutical composition for preventing or treating osteoporosis or decreased female menopausal motility comprising a fermented antler fermented extract by lactic acid bacteria.
하기 실시예에서 녹용 추출물은 골형성 과정에서 발현되는 마커 유전자의 발현을 증가시키며, 녹용 추출물의 발효에 의해 상기 유전자의 발현 증가에 대한 효과가 더욱 증가함을 확인할 수 있었다. 또한 난소를 적출하여 갱년기를 유발한 마우스 모델은 대조군에 비해 마우스의 운동거리와 운동시간이 크게 감소하였으나, 녹용 추출물의 투여에 의해 감소가 다소 완화되었으며, 녹용 추출물을 발효시켜 투여한 경우에는 대조군의 수준으로 회복되었다. 갱년기가 유발된 마우스는 심장, 간 및 비장 무게의 체중비가 대조군에 비해 증가하였으나, 녹용 추출물 및 녹용 발효추출물은 갱년기 모델 마우스에서 각종 장기 무게의 체중비를 대조군의 수준으로 회복시켜, 갱년기로 인한 대사 과정의 변화를 완화시키는 효과가 있음을 보여주었다.In the examples below, it was confirmed that the antler extract increases the expression of marker genes expressed in the process of bone formation, and the effect on the increase in the expression of the gene is further increased by fermentation of the antler extract. Also, in the mouse model in which menopausal was induced by ovarian extraction, the movement distance and exercise time of the mice were significantly reduced compared to the control group, but the decrease was somewhat alleviated by the administration of the antler extract. level was restored. In the menopause-induced mice, the body weight ratio of heart, liver and spleen weights increased compared to the control group, but the antler extract and the antler ferment extract restored the body weight ratio of various organ weights to the level of the control group in the menopause model mice, resulting in metabolism due to menopause. It has been shown to have the effect of mitigating changes in the process.
본 발명에서 사용되는 유산균으로는 Lactobacillus, Lactococcus, Leuconostoc, Pediococcus, Bifidobacterium속의 균주로부터 선택된 하나 이상의 균주를 사용할 수 있다. 배양 기간은 1~3일인 것이 바람직하지만, 상기 범위를 벗어난다고 문제가 되는 것은 아니다. 다만, 배양기간이 너무 짧으면 유산균 발효 효과를 충분히 얻을 수 없고, 배양기간이 너무 길어지면 경제성이 저하되며 각 균주에 따라 최적의 배양조건과 기간을 설정하는 것은 당업자에게 용이할 것이다.As the lactic acid bacteria used in the present invention, one or more strains selected from the genus Lactobacillus, Lactococcus, Leuconostoc, Pediococcus, and Bifidobacterium may be used. The incubation period is preferably 1 to 3 days, but it is not a problem if it is outside the above range. However, if the culture period is too short, the lactic acid bacteria fermentation effect cannot be sufficiently obtained, and if the culture period is too long, the economic feasibility is lowered.
특히 본 발명의 녹용 발효추출물은 유산균의 발효 전 단계에서 녹용 추출물을 단백질 가수분해 효소로 처리하는 것이 더욱 바람직하다. 구체적으로 본 발명의 녹용 발효추출물은 A) 녹용을 C1~C3의 알코올과 물로 이루어진 용매로부터 선택된 하나 이상의 용매를 사용하여 추출하는 단계; B) A) 단계에서 얻어진 녹용 추출물을 단백질 가수분해 효소로 가수분해하는 단계; 및 C) B) 단계의 가수분해 산물을 유산균으로 발효하는 단계;를 포함하여 제조될 수 있다.In particular, in the fermented antler extract of the present invention, it is more preferable to treat the antler extract with a proteolytic enzyme before fermentation of lactic acid bacteria. Specifically, the fermented antler extract of the present invention comprises the steps of: A) extracting the antler using one or more solvents selected from solvents consisting of C1-C3 alcohols and water; B) hydrolyzing the antler extract obtained in step A) with a proteolytic enzyme; And C) the step of fermenting the hydrolysis product of step B) with lactic acid bacteria; can be prepared including.
상기 A) 단계는 녹용의 친수성 유용성분을 추출하는 단계이다. 친수성 유용성분은 통상의 천연물 추출에서와 같이 C1~C3의 알코올과 물로 이루어진 용매로부터 선택된 하나 이상의 용매를 사용하여 추출될 수 있다. 추출은 당업계에서 천연물 추출에 사용되는 방법이라면 어느 것을 사용하여도 무방하며, 예를 들면 냉침, 열추출, 초음파추출 등을 사용할 수 있으나 이에 한정되는 것은 아니다. 추출 시간은 추출온도와 추출방법에 따라 당업자라면 적절히 조절할 수 있을 것이다.Step A) is a step of extracting the hydrophilic useful component of the antler. The hydrophilic useful component may be extracted using one or more solvents selected from solvents consisting of C1-C3 alcohols and water as in conventional extraction of natural products. For extraction, any method used for extracting natural products in the art may be used, for example, cold extraction, heat extraction, ultrasonic extraction, etc. may be used, but the present invention is not limited thereto. The extraction time may be appropriately adjusted by those skilled in the art according to the extraction temperature and extraction method.
상기 B) 단계는 A) 단계에서 얻어진 녹용 추출물을 단백질 가수분해 효소로 가수분해하는 단계이다. 단백질 가수분해 효소로 가수분해 하기 전에, 상기 A) 단계의 추출물은 농축단계를 거칠 수도 있다. 특히, 추출 용매에 C1~C3의 알코올이 포함되어 있는 경우에는 효소 반응을 위하여 용매 중 C1~C3의 알코올을 제거하는 것이 바람직하다.Step B) is a step of hydrolyzing the antler extract obtained in step A) with a proteolytic enzyme. Before hydrolysis with a proteolytic enzyme, the extract of step A) may be subjected to a concentration step. In particular, when the extraction solvent contains C1-C3 alcohol, it is preferable to remove the C1-C3 alcohol from the solvent for the enzymatic reaction.
단백질 가수분해 효소로는 정제된 형태의 효소나 세균성 단백질 가수분해 효소 어느 것을 사용하여도 무방하나, 식품에 사용이 허가된 것을 사용하는 것이 바람직하다. 단백질 가수분해 효소는 예로써 하기 실시예에서 사용된 세균성 단백질 가수분해 효소인 Maxazyme(Bacillus amyloliquefaciens) 이외에도 트립신(Tyrpsin), 뉴트라제(Neutrase), 펩신(pepsin), α-카이모트립신(α-chymotrypsin), 파파인(papain), 프로타맥스(Protamex), 플라보자임(Flavourzyme), 알카라제(Alcalase), 판크레아제(Pancrease) 또는 식품첨가물로서 인정된 각종 세균성 단백질 가수분해 효소를 사용할 수 있으며, 역시 이에 한정되는 것은 아니다. 단백질 가수분해 효소의 처리조건은 사용하는 효소에 따라 최적의 조건을 사용할 수 있음은 당연하다.As the proteolytic enzyme, either a purified form of an enzyme or a bacterial proteolytic enzyme may be used, but it is preferable to use one approved for use in food. Proteolytic enzymes include, for example, trypsin (Tyrpsin), neutrase, pepsin, α-chymotrypsin, in addition to the bacterial proteolytic enzyme Maxazyme ( Bacillus amyloliquefaciens ) used in the Examples below. , Papain, Protamex, Flavozyme, Alcalase, Pancrease, or various bacterial proteolytic enzymes recognized as food additives can be used, Also, the present invention is not limited thereto. It goes without saying that the treatment conditions for the proteolytic enzyme may be optimal depending on the enzyme used.
본 단계에서는 A) 단계에서 얻어진 추출물 중 함유된 고분자 단백질을 가수분해하여 체내로의 흡수를 용이하게 하며, 동물성 소재 특유의 향을 제거하며 농축시 침전물의 형성을 방지하여 관능성을 크게 증가시킬 수 있다. In this step, the high molecular protein contained in the extract obtained in step A) is hydrolyzed to facilitate absorption into the body, and the characteristic flavor of animal material is removed, and the functionality of the extract can be greatly increased by preventing the formation of precipitates upon concentration. have.
C) 단계의 유산균 발효에 의해 본 조성물은 장에서의 흡수가 더욱 용이해지므로, 녹용섭취 시에도 설사를 유발하지 않게 된다. 또한 단백질 가수분해 효소의 처리에 의해 유산균 발효가 더욱 활발하게 진행되며, 전술한 바와 같이 골형성 유전자의 발현 증가와 갱년기 운동성 저하 방지에 더욱 효과적으로 작용한다. Since the composition is more easily absorbed in the intestine by the fermentation of lactic acid bacteria in step C), it does not cause diarrhea even when ingesting antler. In addition, the lactic acid bacteria fermentation proceeds more actively by the treatment of proteolytic enzymes, and as described above, it acts more effectively to increase the expression of osteogenic genes and prevent deterioration of menopausal motility.
본 발명의 조성물은 골다공증 또는 여성 갱년기 운동성 감소의 예방 또는 치료용 약제로 이용하기 위하여, 약제학적 분야에서 공지의 방법에 의하여 제조될 수 있으며, 그 자체 또는 약학적으로 허용되는 담체(carrier), 부형제(forming agent), 희석제 등과 혼합하여 사용될 수 있다. 본 발명의 조성물은 경구 또는 비경구 투여용 제제로 제형화하여 사용할 수 있다. 본 발명에 따른 유효성분의 투여량은 체내에서 활성성분의 흡수도, 제제의 형태, 환자의 연령, 성별 및 상태, 증상의 정도 등에 따라 적절히 선택될 수 있으며, 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 일반적인 투여량은 0.001mg/kg·일~10g/kg·일이다. The composition of the present invention may be prepared by a method known in the pharmaceutical field for use as a medicament for the prevention or treatment of osteoporosis or decreased female menopausal mobility, itself or a pharmaceutically acceptable carrier (carrier), excipient (forming agent), a diluent, etc. may be mixed and used. The composition of the present invention may be formulated and used as a formulation for oral or parenteral administration. The dosage of the active ingredient according to the present invention may be appropriately selected according to the absorption of the active ingredient in the body, the form of the preparation, the age, sex and condition of the patient, the severity of symptoms, etc., and the administration may be administered once a day. , may be administered in several divided doses. A typical dosage is 0.001 mg/kg·day to 10 g/kg·day.
본 발명은 또한 유산균에 의해 발효된 녹용 발효추출물을 포함하는 골다공증 또는 여성 갱년기 운동성 감소의 예방 또는 증상 개선용 건강기능식품 조성물을 제공한다. 상기 건강기능식품 조성물은 건강기능식품으로서 정제, 캡슐제, 환제 또는 액제 등의 형태로 제형화하여 사용할 수 있으며, 또는 각종 식품류, 음료, 껌, 차, 과자, 주류, 초콜릿, 비타민 복합제의 첨가물로 사용할 수 있다. 상기 녹용 발효추출물은 본 발명의 식품 조성물에 바람직하게는 0.01~100 중량%로 하여 첨가될 수 있다.The present invention also provides a health functional food composition for preventing or improving symptoms of osteoporosis or decreased female menopausal motility comprising a fermented antler extract fermented by lactic acid bacteria. The health functional food composition can be formulated and used in the form of tablets, capsules, pills or liquids as health functional food, or as additives of various foods, beverages, gum, tea, sweets, alcoholic beverages, chocolate, and vitamin complexes. Can be used. The fermented antler extract may be added to the food composition of the present invention in an amount of preferably 0.01 to 100% by weight.
이상과 같이 본 발명은 대체의학에서 장기간 안정성이 확보된 녹용 추출물을 활용하여, 호르몬 제제나 호르몬 유사제제 복용에 의한 호르몬 관련 종양의 우려없이 골다공증이나 갱년기 운동성 감소를 효과적으로 예방 또는 치료/증상개선할 수 있어 평균수명 증가에 의한 노령화 사회에서 삶의 질 향상에 기여할 수 있다.As described above, the present invention can effectively prevent or treat/improve symptoms of osteoporosis or decreased menopausal motility without fear of hormone-related tumors caused by taking hormone preparations or hormone analogues by using the antler extract, which has long-term stability in alternative medicine. Therefore, it can contribute to the improvement of the quality of life in an aging society due to the increase in life expectancy.
또한 본 발명은 녹용 추출물을 단백질 가수분해 효소로 가수분해한 후 유산균 발효시키는 것에 의해 장의 흡수를 용이하게 하여 설사를 방지하고, 동물성 식품 특유의 향과 맛을 저감시키고 액상 제품에서 침전의 형성을 억제하므로 우수한 관능성과 녹용 추출물 대비 강화된 효능의 녹용 발효추출물을 제공하여 녹용의 유용성분을 효과적으로 활용할 수 있다. In addition, the present invention prevents diarrhea by facilitating intestinal absorption by hydrolyzing the antler extract with proteolytic enzymes and then fermenting lactic acid bacteria, reduces the unique flavor and taste of animal foods, and suppresses the formation of precipitates in liquid products Therefore, it is possible to effectively utilize the useful ingredients of antler by providing a fermented deer antler extract with superior sensory properties and enhanced efficacy compared to the antler extract.
도 1은 녹용 추출물 및 녹용 발효추출물의 세포독성을 보여주는 그래프.
도 2는 녹용 추출물 및 녹용 발효추출물이 골형성마커 mRNA의 발현에 미치는 영향을 보여주는 그래프.
도 3은 녹용 추출물 및 녹용 발효추출물이 갱년기 모델 마우스의 운동성에 미치는 영향을 보여주는 그래프.
도 4는 녹용 추출물 및 녹용 발효추출물이 갱년기 모델 마우스의 대사에 미치는 영향을 보여주는 그래프.1 is a graph showing the cytotoxicity of the antler extract and the fermented antler extract.
Figure 2 is a graph showing the effect of the antler extract and the fermented antler extract on the expression of bone formation marker mRNA.
Figure 3 is a graph showing the effect of antler extract and fermented antler extract on the motility of menopause model mice.
Figure 4 is a graph showing the effect of the antler extract and the fermented antler extract on the metabolism of the menopause model mouse.
이하 첨부된 실시예를 들어 본 발명을 보다 상세히 설명한다. 그러나 이러한 실시예는 본 발명의 기술적 사상의 내용과 범위를 쉽게 설명하기 위한 예시일 뿐, 이에 의해 본 발명의 기술적 범위가 한정되거나 변경되는 것은 아니다. 이러한 예시에 기초하여 본 발명의 기술적 사상의 범위 안에서 다양한 변형과 변경이 가능함은 당업자에게는 당연할 것이다. Hereinafter, the present invention will be described in more detail with reference to the accompanying examples. However, these embodiments are merely examples for easily explaining the content and scope of the technical idea of the present invention, and thereby the technical scope of the present invention is not limited or changed. It will be natural for those skilled in the art that various modifications and changes can be made within the scope of the technical spirit of the present invention based on these examples.
[실시예][Example]
실시예 1 : 녹용 추출물(DA)의 제조Example 1: Preparation of deer antler extract (DA)
한국산 꽃사슴으로부터 채취한 녹용을 상대, 중대 및 하대로 구분하여 두께가 5 mm 이하가 되도록 얇은 편으로 절단하고, 건조한 것을 상대 : 중대 : 하대의 중량비를 1 : 1 : 1의 비율로 혼합하여 사용하였다. 하기 표 1은 혼합 녹용 절편의 일반 성분 분석 결과의 함량 비(w%)를 나타낸다. Deer antlers collected from Korean deer were divided into upper, middle, and lower antlers, cut into thin slices with a thickness of 5 mm or less, and dried in a weight ratio of 1: 1: 1 and used. . Table 1 below shows the content ratio (w%) of the results of analysis of general components of the mixed antler slices.
혼합 녹용 절편 509.7g과 물 4L를 스테인리스 추출기에 넣고 100℃에서 24시간 추출하였다. 추출액을 여과포로 여과한 후 70℃에서 감압농축하였다. 농축물에 정제수를 가하여 5 Brix로 희석하여 2,940 mL의 추출물을 제조하였으며, 500 mL 씩 폴리프로필렌(PP) 용기에 옮겨 담고 -20℃의 냉동고에 저장하였다. 하기 실시예에서 사용 시에는 냉동된 추출물을 꺼내어 50℃ 수조에서 녹여 사용하였다. 509.7 g of mixed antler slices and 4 L of water were placed in a stainless steel extractor and extracted at 100° C. for 24 hours. The extract was filtered through a filter cloth and concentrated under reduced pressure at 70°C. Purified water was added to the concentrate, diluted with 5 Brix to prepare an extract of 2,940 mL, and 500 mL each was transferred to a polypropylene (PP) container and stored in a freezer at -20°C. When used in the following examples, the frozen extract was taken out and melted in a water bath at 50 ° C.
실시예 2 : 녹용 발효추출물(FDA)의 제조Example 2: Preparation of Fermented Deer Antler Extract (FDA)
실시예 1에서 제조한 녹용 추출물 중 녹용의 단백질을 가수분해하기 위하여 식약처 protease 허가 고시형 제품류 중 Maxazyme NNP DS를 2%(w/v) 농도로 가하여 50℃에서 24시간 효소반응시켰다. 이후 유산균을 2%(w/v) 농도로 첨가하여 37℃ BCP 샬레 배지에서 2일간 배양하였다. 유산균으로는 식약처 유산균 허가 고시형 제품류 중 Mixture of 8 lactobacilli (8종 알파혼합유산균-엘(L)2, 메디오젠)를 사용하였다; In order to hydrolyze the antler protein in the antler extract prepared in Example 1, Maxazyme NNP DS among the products approved by the Ministry of Food and Drug Safety was added at a concentration of 2% (w/v), followed by enzymatic reaction at 50° C. for 24 hours. Thereafter, lactic acid bacteria were added at a concentration of 2% (w/v) and cultured for 2 days at 37° C. in BCP petri dish. As lactic acid bacteria, Mixture of 8 lactobacilli (8 types of alpha mixed lactic acid bacteria-L(L)2, Mediogen) was used among the products approved by the Ministry of Food and Drug Safety;
상기 유산균 발효물에 대해 기능성 식품공전의 유산균 수 측정방법에 준하여 유산균 수를 측정하였다. 먼저 증류수를 기질로 사용한 경우에는 발효 후 유산균이 검출되지 않았으나, 제조예에서 녹용 추출물을 단백질 가수분해 후 유산균 발효시킨 경우에는 배양 후 유산균 수가 2.04×108 cfu/mL였으며, 녹용 추출물을 기질로 하여 유산균 발효한 경우 5.00×107 cfu/mL였다. 이는 녹용 추출물이 유산균 배양에 적합한 영양원으로 활용되며, 단백질 가수분해 효소에 의해 녹용 추출물에 함유된 단백질이 물 가용성 물질이나 아미노산으로 전환되어 유산균 배양에 더 유리한 효과를 나타내는 것으로 사료된다. 또한, 사람이 섭취하였을 때 소화흡수에도 도움이 될 것임을 시사한다.For the lactic acid bacteria fermented product, the number of lactic acid bacteria was measured according to the method for measuring the number of lactic acid bacteria in the functional food industry. First, when distilled water was used as a substrate, lactic acid bacteria were not detected after fermentation. However, when the antler extract was fermented after protein hydrolysis in Preparation Example, the number of lactic acid bacteria after culturing was 2.04×10 8 cfu/mL, and the antler extract was used as a substrate. In the case of lactic acid fermentation, it was 5.00×10 7 cfu/mL. It is believed that the deer antler extract is used as a suitable nutrient source for culturing lactic acid bacteria, and the protein contained in the deer antler extract is converted into water-soluble substances or amino acids by proteolytic enzymes, thereby showing a more favorable effect for culturing lactic acid bacteria. It also suggests that it will help digestion and absorption when ingested by humans.
실시예 3 : 세포독성 평가Example 3: Cytotoxicity evaluation
사람 유래 골아세포인 U2OS와 쥐 유래 대식세포인 RAW264.7에 대한 녹용 추출물(DA)과 녹용 발효추출물(FDA)의 세포독성을 MTS 에세이를 통해 측정하였다. 이를 위하여 U2OS 및 RAW264.7 세포를 96-웰 플레이트에 분주하고, 녹용 추출물 또는 녹용 발효추출물을 0, 0.13, 0.25, 0.50, 1.00 또는 2.00 mg/mL의 농도로 가하여 24시간 처리한 후 MTS assay 방법을 이용하여 세포생존율을 측정하였다.The cytotoxicity of antler extract (DA) and fermented antler extract (FDA) to U2OS, a human osteoblast, and RAW264.7, a mouse-derived macrophage, was measured through MTS assay. To this end, U2OS and RAW264.7 cells were aliquoted into a 96-well plate, and the antler extract or antler ferment extract was added at a concentration of 0, 0.13, 0.25, 0.50, 1.00 or 2.00 mg/mL and treated for 24 hours, followed by the MTS assay method. was used to measure cell viability.
도 1은 그 결과를 도시한 것으로, 녹용 추출물 및 녹용 발효추출물을 2.0 mg/mL 농도까지 처리한 결과, 유의미한 세포 활성도의 변화는 확인되지 않아 세포 독성없이 안전하게 사용할 수 있음을 확인할 수 있었다.Figure 1 shows the results, and as a result of treating the antler extract and the fermented antler extract to a concentration of 2.0 mg/mL, no significant change in cell activity was confirmed, so it could be confirmed that it could be safely used without cytotoxicity.
실시예 4 : 골형성에 대한 녹용 발효추출물의 영향 평가Example 4: Evaluation of the effect of fermented deer antler extract on bone formation
인간 골아세포인 U2OS에 실시예 1과 실시예 2에서 제조한 녹용 추출물 및 녹용 발효추출물을 1.0 또는 2.0 mg/mL의 농도로 처리하여 48시간동안 배양하고 골아세포의 골형성 과정에서 발현되는 마커 유전자 RUNX2, SP7 및 OCN의 발현량을 rtPCR로 정량하였다. 발현량은 GAPHD의 발현량에 대한 상대적 mRNA 발현량으로 측정하였으며, 표 2에 rtPCR에 사용된 프라이머의 서열을 기재하였다.Human osteoblast U2OS was treated with the antler extract and antler ferment extract prepared in Examples 1 and 2 at a concentration of 1.0 or 2.0 mg/mL, cultured for 48 hours, and a marker gene expressed in the osteoblastic process of osteoblasts. Expression levels of RUNX2, SP7 and OCN were quantified by rtPCR. The expression level was measured as the mRNA expression level relative to the expression level of GAPHD, and the sequences of the primers used for rtPCR are described in Table 2.
도 2는 골분화 마커 유전자의 발현량을 보여주는 결과로, RUNX2 mRNA는 녹용 발효추출물에 의해 발현량이 변화하지 않거나, 다소 감소하는 경향을 나타내었으나, SP7 및 OCN 유전자의 발현량은 크게 증가하였다. 구체적으로 OCN mRNA는 녹용 추출물 투여 시에는 대조군과 유의적인 차이가 없었으나, 녹용 발효추출물은 1.0 mg/mL 투여시에도 유의적인 변화를 나타내었으며 20 mg/mL 처리 시에는 대조군에 비해 1.28배 발현이 증가하였다. SP7 mRNA는 녹용 추출물과 녹용 발효추출물의 투여에 의해 모두 유의적으로 발현이 증가하였는데, 대조군에 비해 녹용 추출물 2.0 mg/mL를 처리하였을 때에는 1.52배, 녹용 발효추출물 2.0 mg/mL를 처리하였을 때에는 2.31배 발현이 증가함을 확인할 수 있었다. 2 is a result showing the expression level of the osteogenic differentiation marker gene. RUNX2 mRNA did not change or showed a tendency to decrease slightly by the fermented deer antler extract, but the expression level of the SP7 and OCN genes was greatly increased. Specifically, OCN mRNA was not significantly different from that of the control group when the antler extract was administered, but the fermented antler extract showed a significant change even when administered at 1.0 mg/mL. increased. SP7 mRNA was significantly increased by the administration of both the antler extract and the fermented antler extract, 1.52 times when treated with 2.0 mg/mL of the antler extract, and 2.31 times when treated with 2.0 mg/mL of the antler fermented extract. It was confirmed that the embryo expression increased.
이 결과는 녹용 추출물은 골형성을 촉진시키는 효능이 있으며, 이러한 효능이 발효를 통하여 강화되었음을 나타낸다.This result indicates that the deer antler extract has the effect of promoting bone formation, and this effect was enhanced through fermentation.
실시예 5 : 운동성에 대한 녹용 발효추출물의 영향 평가Example 5: Evaluation of the effect of fermented deer antler extract on motility
트레드밀 테스트(treadmill test)에 의해 녹용 추출물 및 녹용 발효추출물이 쥐의 운동성에 미치는 영향을 평가하였다. 마우스는 ~ 주령의 C67BL/6 마우스를 1주일간 순화 후 난소적출(OVX)를 통해 폐경기 상태를 유도하였다.The effect of the antler extract and the fermented antler extract on the motility of mice was evaluated by the treadmill test. Mice were acclimatized to ~week-old C67BL/6 mice for 1 week and then induced menopause through ovariectomy (OVX).
이후, 1주일간 회복기를 가진 뒤 12주간 25℃, 12시간 낮/밤 주기를 제공하는 환경 속에서 녹용 추출물 또는 녹용 발효추출물을 배합사료와 혼합하여 충분한 물과 함께 자유급이하였다. 12주 후 0° 경사에서 10 cm/sec부터 45 cm/sec로 점진적으로 속도를 올리며 10초 이상 뒤처질 때까지 트레드밀 테스트를 진행하였다. 운동성은 운동거리와 운동시간을 기준으로 하여 비교하였으며, 도 3은 그 결과를 나타낸다. 난소 적출 집단의 운동거리는 346.6±70.7 m로 476.6±76.3 m 이동한 대조군에 비하여 감소하는 것이 확인되었으나 녹용 추출물을 섭취한 집단에서는 417.4±90.8 m, 녹용 발효추출물을 섭취한 집단에서는 453.6±62.6 m로 운동성이 회복됨을 보여준다. 운동시간 역시 난소 적출에 의해 유의적으로 감소하였으나, 녹용 추출물의 복용에 의해 회복되는 것을 보여주며, 녹용 발효추출물은 대조군과 유사한 운동시간을 나타내었다.Thereafter, after having a recovery period for one week, the antler extract or fermented antler extract was mixed with the formulated feed in an environment providing a 12-week day/night cycle at 25° C. for 12 weeks, and it was fed ad libitum with sufficient water. After 12 weeks, the treadmill test was conducted until the speed was gradually increased from 10 cm/sec to 45 cm/sec at a 0° inclination and lagged behind by more than 10 seconds. Mobility was compared based on the exercise distance and exercise time, and FIG. 3 shows the results. The movement distance of the ovariectomized group was 346.6±70.7 m, which decreased compared to the control group that moved 476.6±76.3 m, but it was 417.4±90.8 m in the group taking the antler extract and 453.6±62.6 m in the group taking the antler ferment extract. It shows that mobility is restored. Exercise time was also significantly decreased by ovariectomy, but it was recovered by taking the antler extract, and the fermented antler extract showed exercise time similar to that of the control group.
즉, 골형성 촉진 효능과 마찬가지로 녹용 추출물은 난소 적출에 의한 쥐의 운동성 감소를 회복시키며, 녹용 추출물의 발효에 의해 이러한 효능이 강화되는 것을 확인할 수 있었다.That is, it was confirmed that the antler extract restores the decrease in motility of mice due to ovariectomy, and this effect is enhanced by the fermentation of the antler extract, similar to the bone formation promoting effect.
트레드밀 테스트가 종료된 후 마우스를 희생시키고 심장, 간 및 비장을 적출하여 무게를 측정하는 것에 의해 녹용 추출물 및 녹용 발효추출물이 대사에 미치는 영향을 확인하였다. 그 결과, 도 4에서 보여주듯이 난소 적출에 의해 증가한 심장, 간, 비장의 체중에 대한 무게비가 녹용 추출물 또는 녹용 발효추출물의 복용에 의해 대조군의 수준으로 회복되었다. After the treadmill test was completed, mice were sacrificed, and the heart, liver and spleen were removed and weighed to determine the effect of the antler extract and the fermented antler extract on metabolism. As a result, as shown in FIG. 4 , the weight-to-weight ratio of the heart, liver, and spleen increased by ovariectomy was restored to the level of the control group by taking the antler extract or fermented antler extract.
<110> SEOWON UNIVERSITY INSTITUTE OF INDUSTRY-ACADEMY COLLABORATION <120> Composition for Prophylaxis or Treatment of Osteoporosis or Menopause-Related Decreased Motility Comprising Fermented Antler Extract <130> P0321-155 <160> 8 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 1 tggacgaggc aagagtttca 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 2 tcccgaggtc catctactgt 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 3 gatctggtgc ctagaagccc 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 4 caagctccag cggctttaac 20 <210> 5 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 5 gctccagggg atccgggta 19 <210> 6 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 6 aagcccagcg gtgcagagt 19 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 7 ttgaggtcaa tgaaggggtc 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 8 gaaggtgaag gtcggagtca 20 <110> SEOWON UNIVERSITY INSTITUTE OF INDUSTRY-ACADEMY COLLABORATION <120> Composition for Prophylaxis or Treatment of Osteoporosis or Menopause-Related Decreased Motility Comprising Fermented Antler Extract <130> P0321-155 <160> 8 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 1 tggacgaggc aagagtttca 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 2 tcccgaggtc catctactgt 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 3 gatctggtgc ctagaagccc 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 4 caagctccag cggctttaac 20 <210> 5 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 5 gctccagggg atccgggta 19 <210> 6 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 6 aagcccagcg gtgcagagt 19 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 7 ttgaggtcaa tgaaggggtc 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 8 gaaggtgaag gtcggagtca 20
Claims (4)
A pharmaceutical composition for preventing or treating osteoporosis or decreased female menopausal mobility, comprising a fermented antler ferment extract fermented by lactic acid bacteria.
상기 유산균은 Lactobacillus, Lactococcus, Leuconostoc, Pediococcus, Bifidobacterium속의 균주로부터 선택된 하나 이상인 것을 특징으로 하는 골다공증 또는 여성 갱년기 운동성 감소의 예방 또는 치료용 약학 조성물.
The method according to claim 1,
The lactic acid bacteria is Lactobacillus, Lactococcus, Leuconostoc, Pediococcus, a pharmaceutical composition for the prevention or treatment of osteoporosis or reduced female menopausal mobility, characterized in that at least one selected from the strains of the genus Bifidobacterium.
A) 녹용을 C1~C3의 알코올과 물로 이루어진 용매로부터 선택된 하나 이상의 용매를 사용하여 추출하는 단계;
B) A) 단계에서 얻어진 녹용 추출물을 단백질 가수분해 효소로 가수분해하는 단계; 및
C) B) 단계의 가수분해 산물을 유산균으로 발효하는 단계;
를 포함하여 제조되는 것을 특징으로 하는 골다공증 또는 여성 갱년기 운동성 감소의 예방 또는 치료용 약학 조성물.
The method according to claim 1 or 2,
A) extracting the deer antler using one or more solvents selected from solvents consisting of C1-C3 alcohols and water;
B) hydrolyzing the antler extract obtained in step A) with a proteolytic enzyme; and
C) fermenting the hydrolysis product of step B) with lactic acid bacteria;
A pharmaceutical composition for the prevention or treatment of osteoporosis or decreased female menopausal motility, characterized in that it is prepared including a.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210035876A KR102488062B1 (en) | 2021-03-19 | 2021-03-19 | Composition for Prophylaxis or Treatment of Menopause-Related Decreased Motility Comprising Fermented Antler Extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210035876A KR102488062B1 (en) | 2021-03-19 | 2021-03-19 | Composition for Prophylaxis or Treatment of Menopause-Related Decreased Motility Comprising Fermented Antler Extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220130966A true KR20220130966A (en) | 2022-09-27 |
KR102488062B1 KR102488062B1 (en) | 2023-01-12 |
Family
ID=83451775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210035876A KR102488062B1 (en) | 2021-03-19 | 2021-03-19 | Composition for Prophylaxis or Treatment of Menopause-Related Decreased Motility Comprising Fermented Antler Extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102488062B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115990192A (en) * | 2022-12-20 | 2023-04-21 | 长春科技学院 | Application of pilose antler stem cell exosome in treatment and prevention of osteoporosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100397220B1 (en) | 2000-07-13 | 2003-09-13 | 전길자 | Extract of deer antler containing bone formation enhancing activity and its purifying method |
KR20190050294A (en) * | 2017-11-02 | 2019-05-10 | 경희대학교 산학협력단 | Novel lactic acid bacteria and use thereof |
-
2021
- 2021-03-19 KR KR1020210035876A patent/KR102488062B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100397220B1 (en) | 2000-07-13 | 2003-09-13 | 전길자 | Extract of deer antler containing bone formation enhancing activity and its purifying method |
KR20190050294A (en) * | 2017-11-02 | 2019-05-10 | 경희대학교 산학협력단 | Novel lactic acid bacteria and use thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115990192A (en) * | 2022-12-20 | 2023-04-21 | 长春科技学院 | Application of pilose antler stem cell exosome in treatment and prevention of osteoporosis |
Also Published As
Publication number | Publication date |
---|---|
KR102488062B1 (en) | 2023-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2995304B1 (en) | Germinated and fermented bean extract and cosmetic or food use of a germinated and fermented bean extract | |
KR101734960B1 (en) | Leuconostoc holzapfelii stain for preventing depilation, improving hair growth or improving sexual disfunction, and composition comprising the same | |
JP2021088602A (en) | Compositions for improving bone health comprising functional fermentation products using oysters | |
CN112999261A (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
KR20180104544A (en) | Composition for treating or preventing of arthritis, fibrosis, colitis or transplant rejection comprising Lactobacillus Acidophilus | |
US10729737B2 (en) | Muscle-enhancing agent | |
JP2002179585A (en) | Bone metabolism improver and food/drink for preventing or treating osteoporosis | |
KR102488062B1 (en) | Composition for Prophylaxis or Treatment of Menopause-Related Decreased Motility Comprising Fermented Antler Extract | |
US20090196867A1 (en) | Soy kefir powder and uses thereof | |
KR101790548B1 (en) | Composition for preventing depilation or improving hair growth comprising a stain having lipolysis ability | |
KR20200000146A (en) | Composition for preventing or treating Peyronie's disease comprising Vitrin inhibitor | |
AU2019416609B2 (en) | Kimchi for preventing or treating helicobacter pylori-associated diseases | |
CN115969961A (en) | Calcium, VD and protein peptide composition for improving bone mineral density and preparation method and application thereof | |
KR20200065170A (en) | Composition for Prophylaxis and Treatment of Osteoporosis, Diabetes and Obesity Comprising Fermented Tremella fuciformis Berk. | |
KR101794771B1 (en) | Brevibacillus reuszeri stain for preventing depilation, improving hair growth or improving sexual disfunction, and composition comprising the same | |
JP4993817B2 (en) | Bone metabolism improving agent and food for preventing or treating osteoporosis | |
KR102379612B1 (en) | Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva | |
EP4074324A1 (en) | Composition containing enteroccocus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby | |
CN112153976B (en) | Composition for preventing or treating osteoporosis | |
KR20140106058A (en) | Composition for enhancing immunological activity comprising soluble salmon milt extract and vegetable lactic acid bacteria | |
KR20240025125A (en) | Composition for Prevention or Treatment of Osteoporosis or Menopause-Related Decreased Motility Comprising Fermented Antler Extract | |
KR20140107051A (en) | Composition for prevention or treatment of anorexia comprising menispermum dauricum DC, menispermum dauricum DC extract, menispermum dauricum DC sludge or menisperum dauricum DC malt fermented liquid extract | |
JP2004065156A (en) | Method for producing composition for inhibiting onset of liver cancer, and composition | |
JP2006006156A (en) | Liver function-enhancing health food | |
JP2008239521A (en) | Angiotensin-converting enzyme inhibitor and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |